Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mark R. Hellberg is active.

Publication


Featured researches published by Mark R. Hellberg.


Survey of Ophthalmology | 2002

Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist

Mark R. Hellberg; Marsha A. McLaughlin; Naj Sharif; Louis Desantis; Thomas R. Dean; Evan P. Kyba; John E. Bishop; Peter G. Klimko; Paul W. Zinke; Robert D. Selliah; George Barnes; Joseph M. deFaller; Angela C. Kothe; Theresa A. Landry; E. Kenneth Sullivan; Russell Andrew; Alberta A Davis; Lewis H. Silver; Michael V.W. Bergamini; Stella M. Robertson; Alan L. Weiner; Verney L. Sallee

The structure-activity studies that led to the identification of travoprost, a highly selective and potent FP prostaglandin analog, and AL-6598, a DP prostaglandin analog, are detailed. In both series, the 1-alcohol analogs are very effective and are thought to be acting as prodrugs for the biologically active carboxylic acids. The efficacy of amide prodrugs depends on the degree of substitution and the size of the substituents. Selected compounds are profiled in vitro and in vivo preclinically. Clinical studies show that travoprost 0.004% (isopropyl ester) provided intraocular pressure control superior to timolol 0.5% when used as monotherapy in patients with open-angle glaucoma or ocular hypertension. In clinical studies, AL-6598 0.01% provided a sustained intraocular pressure reduction with q.d. application; b.i.d. provided greater intraocular pressure control. The acute and, apparently, conjunctival hyperemia associated with topical ocular AL-6598 can be attenuated while maintaining intraocular pressure-lowering efficacy by formulating with brimonidine.


Journal of Ocular Pharmacology and Therapeutics | 2003

The Hydrolysis of the Prostaglandin Analog Prodrug Bimatoprost to 17-Phenyl-trinor PGF2α by Human and Rabbit Ocular Tissue

Mark R. Hellberg; Tai-Lee Ke; Karen Haggard; Peter G. Klimko; Thomas R. Dean; Gustav Graff

Bimatoprost (Lumigan), the ethyl amide derivative of the potent prostaglandin FP agonist 17-phenyl-trinor PGF(2alpha), has been reported to be a member of a pharmacologically unique class of ocular hypotensive agents. To confirm that bimatoprost, which is intrinsically active as an FP prostaglandin agonist, is also a prostaglandin analog prodrug, the hydrolysis of bimatoprost by ocular tissues was studied by incubating solutions containing bimatoprost with either human or rabbit ocular tissue. The ethyl amide group of bimatoprost was hydrolyzed by rabbit and human cornea, iris/ciliary body and Thasclera to produce the expected carboxylic acid product, 17-phenyl-trinor PGF(2alpha). The rate of hydrolysis by human and rabbit cornea and iris/ciliary body is similar, whereas the rate of hydrolysis by the sclera is slower in humans than in rabbits. These studies show that human and rabbit ocular tissue (cornea, iris/ciliary body and sclera) can convert bimatoprost to the potent prostaglandin FP agonist 17-phenyl-trinor PGF(2alpha). Separate in vitro studies clearly show that both bimatoprost and 17-phenyl-trinor PGF(2alpha) have affinity for and are agonists at the human FP receptor. Taken together, the data strongly suggests that the ocular hypotensive effect of bimatoprost can be attributed to its activity as a prostaglandin receptor agonist either directly or through its role as a prostaglandin agonist prodrug.


Investigative Ophthalmology & Visual Science | 2011

Agonists at the Serotonin Receptor (5-HT1A) Protect the Retina from Severe Photo-Oxidative Stress

R. J. Collier; Yamini Patel; E. Martin; Olga Dembinska; Mark R. Hellberg; D. Scott Krueger; Michael A. Kapin; Carmelo Romano

PURPOSE 5-HT(1A) agonists are neuroprotective in CNS injury models. The authors evaluated the efficacy of 5-HT(1A) agonists to protect the retina from severe blue light-induced photo-oxidative damage. METHODS Albino rats were dosed (subcutaneously) with AL-8309A, 8-OH DPAT, or buspirone once or three times before 6-hour exposure to blue light. Electroretinograms (ERGs) were measured to assess retinal function, and retinal damage was evaluated by light microscopy. Topical ocular dosing with 1.75% AL-8309B was also evaluated. Rats were dosed with WAY-100635, a 5-HT(1A) antagonist, to determine whether protection required activation of the 5-HT(1A) receptor. RESULTS ERG response amplitudes were significantly (P < 0.05) depressed more than 66% in vehicle-dosed rats after light exposure. ERGs were significantly higher in rats treated with AL-8309A (0.1-30 mg/kg), 8-OH DPAT (0.1-1 mg/kg), buspirone (5-20 mg/kg) or topical ocular with 1.75% AL-8309B. Retinas from AL-8309A and 8-OH DPAT-treated rats were devoid of histologic lesions. Significant protection was measured in rats dosed once 0, 24, or 48 hours before light exposure. Protection provided by dosing with AL-8309B or 8-OH DPAT was inhibited in rats predosed with WAY-100635. CONCLUSIONS 5-HT(1A) agonists provided potent and complete functional and structural protection. Protection was inhibited by treatment with WAY-100635, confirming the requirement for activating the 5-HT(1A) receptor in initiating this survival pathway. Single-dose experiments with AL-8309A suggest that the mechanism of protection is rapidly activated and protection persists for 48 hours. AL-8309B (1.75%) was effective after topical ocular dosing. AL-8309B is under evaluation in the clinic and may be useful in treating age-related macular degeneration.


Bioorganic & Medicinal Chemistry Letters | 2010

2,3-Diaminopyrazines as rho kinase inhibitors

Alan J. Henderson; Mark Hadden; Cheng Guo; Neema Douglas; Hélène Decornez; Mark R. Hellberg; Andrew Rusinko; Marsha McLaughlin; Naj Sharif; Colene D. Drace; Raj Patil

Inhibition of rho kinase (ROCK) has been recognized as an important target for a number of diseases, including glaucoma. Herein we report SAR development around two hits from a kinase library that led to the discovery of the ROCK inhibitor compound 38. In vitro and in vivo analysis of this compound, including its effects in a monkey model of glaucoma will be discussed.


Bioorganic & Medicinal Chemistry | 2002

3-Oxa-15-cyclohexyl Prostaglandin DP Receptor Agonists as Topical Antiglaucoma Agents

Mark R. Hellberg; Raymond E. Conrow; Najam A. Sharif; Marsha A. McLaughlin; John E. Bishop; Julie Y. Crider; W. Dennis Dean; Kevin A. DeWolf; David R. Pierce; Verney L. Sallee; Robert D. Selliah; Bryon S. Severns; Steven J. Sproull; Gary W. Williams; Paul W. Zinke; Peter G. Klimko

A series of prostaglandin DP agonists containing a 3-oxa-15-cyclohexyl motif was synthesized and evaluated in several in vitro and in vivo biological assays. The reference compound ZK 118.182 (9beta-chloro-15-cyclohexyl-3-oxa-omega-pentanor PGF(2alpha)) is a potent full agonist at the prostaglandin DP receptor. Saturation of the 13,14 olefin affords AL-6556, which is less potent but is still a full agonist. Replacement of the 9-chlorine with a hydrogen atom or inversion of the carbon 15 stereochemistry also reduces affinity. In in vivo studies ZK 118.182 lowers intraocular pressure (IOP) upon topical application in the ocular hypertensive monkey. Ester, 1-alcohol, and selected amide prodrugs of the carboxylic acid enhance in vivo potency, presumably by increasing bioavailability. The clinical candidate AL-6598, the isopropyl ester prodrug of AL-6556, produces a maximum 53% drop in monkey IOP with a 1 microg dose (0.003% w/w) using a twice-daily dosing regime. Synthetically, AL-6598 was accessed from known intermediate 1 using a novel key sequence to install the cis allyl ether in the alpha chain, involving a selective Swern oxidative desilylation of a primary silyl ether in the presence of a secondary silyl ether. In this manner, 136 g of AL-6598 was synthesized under GMP conditions for evaluation in phase I clinical trials.


Bioorganic & Medicinal Chemistry Letters | 2010

Benzothiophene containing Rho kinase inhibitors: Efficacy in an animal model of glaucoma

Robert L. Davis; Mehmet Kahraman; Thomas J. Prins; Yan Beaver; Travis G. Cook; Jessica Cramp; Charmagne S. Cayanan; Elisabeth M.M. Gardiner; Marsha A. McLaughlin; Abbot F. Clark; Mark R. Hellberg; Andrew K. Shiau; Stewart A. Noble; Allen J. Borchardt

We identified a new benzothiophene containing Rho kinase inhibitor scaffold in an ultra high-throughput enzymatic activity screen. SAR studies, driven by a novel label-free cellular impedance assay, were used to derive 39, which substantially reduced intraocular pressure in a monkey model of glaucoma-associated ocular hypertension.


Bioorganic & Medicinal Chemistry Letters | 2010

Water-soluble PDE4 inhibitors for the treatment of dry eye.

Steven P. Govek; Guy Oshiro; John V. Anzola; Clay Beauregard; Jasmine Chen; Avery R. Coyle; Daniel A. Gamache; Mark R. Hellberg; Jennifer N. Hsien; Julia M. Lerch; John Liao; James W. Malecha; Lena M. Staszewski; David J. Thomas; John M. Yanni; Stewart A. Noble; Andrew K. Shiau

PDE4 inhibitors have the potential to alleviate the symptoms and underlying inflammation associated with dry eye. Disclosed herein is the development of a novel series of water-soluble PDE4 inhibitors. Our studies led to the discovery of coumarin 18, which is effective in a rabbit model of dry eye and a tear secretion test in rats.


Bioorganic & Medicinal Chemistry Letters | 2014

In vivo optimization of 2,3-diaminopyrazine Rho Kinase inhibitors for the treatment of glaucoma

Hwang-Hsing Chen; Abdelmoulah Namil; Bryon S. Severns; Jennifer Ward; Curtis R. Kelly; Colene D. Drace; Marsha McLaughlin; Shenouda Yacoub; Byron Li; Raj Patil; Naj Sharif; Mark R. Hellberg; Andrew Rusinko; Iok-Hou Pang; Keith D. Combrink

A series of 2,3,6-pyrazine Rho Kinase inhibitors were optimized for in vivo activity for topical ocular dosing. Modifications of the 2-(piperazin-1-yl)pyrazine derivatives produced compounds with improved solubility and physicochemical properties. Modifications of the 6-pyrazine substituent led to improvements in in vitro potency. Compound 9 had the best in vitro and in vivo potency of EC50=260 nM with a 30% reduction of IOP in a non-human primate model at a dose of 0.33%.


Bioorganic & Medicinal Chemistry | 2009

Discovery of 13-oxa prostaglandin analogs as antiglaucoma agents: Synthesis and biological activity

Zixia Feng; Mark R. Hellberg; Najam A. Sharif; Marsha A. McLaughlin; Gary W. Williams; Daniel Scott; Tony Wallace

FP-Class prostaglandin analogs have demonstrated utility for the treatment of glaucoma and ocular hypertension. A series of novel FP prostaglandin analogs was designed to optimize topical ocular activity and reduce ocular side-effects by replacing 13-carbon with oxygen. A facile synthesis was successfully developed for synthesis of the 13-oxa prostaglandins from the commercially available Corey aldehyde benzoate. Among the compounds synthesized, AL-16082 was the most potent prostaglandin FP agonist in vitro. In a prostaglandin FP receptor-linked second-messenger assay, phosphoinositide (PI) turnover, it exhibited a potency value (EC(50)) of 1.9 nM (78% max. response relative to fluprostenol). The isopropyl ester of AL-16082, compound AL-16049, significantly lowered intraocular pressure (IOP) in the ocular hypertensive monkey eyes by 30%. In the study of acute ocular irritation response in New Zealand albino rabbits, AL-16049 produced lower incidence of hyperemia, swelling, and discharge than PGF(2alpha) (1 microg), and a similar incidence of hyperemia, swelling, and discharge to latanoprost (1.8 microg). AL-16049 also produced no signs of ocular irritation or discomfort in the cat at the doses evaluated.


Journal of Medicinal Chemistry | 2015

Ocular Hypotensive Response in Nonhuman Primates of (8R)-1-[(2S)-2-Aminopropyl]-8,9-dihydro-7H-pyrano[2,3-g]indazol-8-ol a Selective 5-HT2 Receptor Agonist

Jesse A. May; Najam A. Sharif; Marsha A. McLaughlin; Hwang-Hsing Chen; Bryon S. Severns; Curtis R. Kelly; William F. Holt; Richard Young; Richard A. Glennon; Mark R. Hellberg; Thomas R. Dean

Recently, it has been reported that 5-HT2 receptor agonists effectively reduce intraocular pressure (IOP) in a nonhuman primate model of glaucoma. Although 1-[(2S)-2-aminopropyl]indazol-6-ol (AL-34662) was shown to have good efficacy in this nonhuman primate model of ocular hypertension as well as a desirable physicochemical and permeability profile, subsequently identified cardiovascular side effects in multiple species precluded further clinical evaluation of this compound. Herein, we report selected structural modifications that resulted in the identification of (8R)-1-[(2S)-2-aminopropyl]-8,9-dihydro-7H-pyrano[2,3-g]indazol-8-ol (13), which displayed an acceptable profile to support advancement for further preclinical evaluation as a candidate for proof-of-concept studies in humans.

Collaboration


Dive into the Mark R. Hellberg's collaboration.

Researchain Logo
Decentralizing Knowledge